Latest Findings on the Role of RUNX1 in Bone Development and Disorders

PAN Zijian, ZHOU Xue'er, CAO Zhiwei, PAN Jian


Runt-related transcription factor (RUNX1) is a transcription factor closely involved in hematopoiesis. RUNX1 gene mutation plays an essential pathogenic role in the initiation and development of hematological tumors, especially in acute myeloid leukemia. Recent studies have shown that RUNX1 is also involved in the regulation of bone development and the pathological progression of bone-related diseases. RUNX1 promotes the differentiation of mesenchymal stem cells into chondrocytes and osteoblasts and modulates the maturation and extracellular matrix formation of chondrocytes. The expression of RUNX1 in mesenchymal stem cells, chondrocytes, and osteoblasts is of great significance for maintaining normal bone development and the mass and quality of bones. RUNX1 also inhibits the differentiation and bone resorptive activities of osteoclasts, which may be influenced by sexual dimorphism. In addition, RUNX1 deficiency contributes to the pathogenesis of osteoarthritis, delayed fracture healing, and osteoporosis, which was revealed by the RUNX1 conditional knockout modeling in mice. However, the roles of RUNX1 in regulating the hypertrophic differentiation of chondrocytes, the sexual dimorphism of activities of osteoclasts, as well as bone loss in diabetes mellitus, senescence, infection, chronic inflammation, etc, are still not fully understood. This review provides a systematic summary of the research progress concerning RUNX1 in the field of bone biology, offering new ideas for using RUNX1 as a potential target for bone related diseases, especially osteoarthritis, delayed fracture healing, and osteoporosis.


Keywords: RUNX1, Bone biology, Bone development, Osteoarthritis, Review


Full Text:



VIMALRAJ S, SEKARAN S. RUNX Family as a promising biomarker and a therapeutic target in bone cancers: a review on its molecular mechanism(s) behind tumorigenesis. Cancers (Basel),2023,15(12): 3247. doi: 10.3390/cancers15123247.

MEVEL R, DRAPER J E, LIE A L M, et al. RUNX transcription factors: orchestrators of development. Development,2019,146(17): dev148296. doi: 10.1242/dev.148296.

HOJO H, OHBA S. Runt-related transcription factors and gene regulatory mechanisms in skeletal development and diseases. Curr Osteoporos Rep,2023,21(5): 485–492. doi: 10.1007/s11914-023-00808-4.

DÍAZ-HERNÁNDEZ M E, KINTER C W, WATSON S R, et al. Sexually dimorphic increases in bone mass following tissue-specific overexpression of Runx1 in osteoclast precursors. Endocrinology,2022,163(9): bqac113. doi: 10.1210/endocr/bqac113.

ZHOU C, CUI Y, YANG Y, et al. Runx1 protects against the pathological progression of osteoarthritis. Bone Res,2021,9(1): 50. doi: 10.1038/s41413-021-00173-x.

ARIFFIN N S. RUNX1 as a novel molecular target for breast cancer. Clin Breast Cancer,2022,22(6): 499–506. doi: 10.1016/j.clbc.2022.04.006.

ROZEN E J, OZEROFF C D, ALLEN M A. RUN(X) out of blood: emerging RUNX1 functions beyond hematopoiesis and links to Down syndrome. Hum Genomics,2023,17(1): 83. doi: 10.1186/s40246-023-00531-2.

RIDDELL A, MCBRIDE M, BRAUN T, et al. RUNX1: an emerging therapeutic target for cardiovascular disease. Cardiovasc Res,2020, 116(8): 1410–1423. doi: 10.1093/cvr/cvaa034.

ROY A, CHAUHAN S, BHATTACHARYA S, et al. Runt-related transcription factors in human carcinogenesis: a friend or foe? J Cancer Res Clin Oncol,2023,149(11): 9409–9423. doi: 10.1007/s00432-023-04769-0.

HAYASHI Y, HARADA Y, HARADA H. Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective. Leukemia,2022,36(5): 1203–1214. doi: 10.1038/s41375-022-01548-7.

SEO W, TANIUCHI I. The roles of RUNX family proteins in development of immune cells. Mol Cells,2020,43(2): 107–113. doi: 10. 14348/molcells.2019.0291.

CHIN P S, BONIFER C. Modelling t(8;21) acute myeloid leukaemia -What have we learned? MedComm (2020),2020,1(3): 260–269. doi: 10. 1002/mco2.30.

SHRESTHA B R, WU L, GOODRICH L V. Runx1 controls auditory sensory neuron diversity in mice. Dev Cell,2023,58(4): 306–319.e305. doi: 10.1016/j.devcel.2023.01.008.

NICOL B, GRIMM S A, CHALMEL F, et al. RUNX1 maintains the identity of the fetal ovary through an interplay with FOXL2. Nat Commun,2019,10(1): 5116. doi: 10.1038/s41467-019-13060-1.

MA H, JIANG S, YUAN Y, et al. RUNX1 promotes proliferation and migration in non-small cell lung cancer cell lines via the mTOR pathway. FASEB J,2023,37(11): e23195. doi: 10.1096/fj.202300687RR.

CHAGIN A S, CHU T L. The origin and fate of chondrocytes: cell plasticity in physiological setting. Curr Osteoporos Rep,2023,21(6): 815–824. doi: 10.1007/s11914-023-00827-1.

BAČENKOVÁ D, TREBUŇOVÁ M, DEMETEROVÁ J, et al. Human chondrocytes, metabolism of articular cartilage, and strategies for application to tissue engineering. Int J Mol Sci,2023,24(23): 17096. doi: 10.3390/ijms242317096.

WANG Y, BELFLOWER R M, DONG Y F, et al. Runx1/AML1/Cbfa2 mediates onset of mesenchymal cell differentiation toward chondrogenesis. J Bone Miner Res,2005,20(9): 1624–1636. doi: 10.1359/jbmr.050516.

KIMURA A, INOSE H, YANO F, et al. Runx1 and Runx2 cooperate during sternal morphogenesis. Development,2010,137(7): 1159–1167. doi: 10.1242/dev.045005.

TANG C Y, CHEN W, LUO Y, et al. Runx1 up-regulates chondrocyte to osteoblast lineage commitment and promotes bone formation by enhancing both chondrogenesis and osteogenesis. Biochem J,2020, 477(13): 2421–2438. doi: 10.1042/bcj20200036.

YANO F, OHBA S, MURAHASHI Y, et al. Runx1 contributes to articular cartilage maintenance by enhancement of cartilage matrix production and suppression of hypertrophic differentiation. Sci Rep, 2019,9(1): 7666. doi: 10.1038/s41598-019-43948-3.

AMARASEKARA D S, KIM S, RHO J. Regulation of osteoblast differentiation by cytokine networks. Int J Mol Sci,2021,22(6): 2851. doi: 10.3390/ijms22062851.


  • There are currently no refbacks.